Organic cyanylating reagent; Biochemical assay reagents
CDAP does not have a defined biological target as a therapeutic agent. It is a chemical reagent used in peptide synthesis and bioconjugation. The compound is not intended to exert pharmacological effects. Its utility lies in its chemical properties as an activating agent for amide bond formation. It is not characterized for direct biological activities such as enzyme inhibition or receptor modulation.

In this work, researchers used an organic cyanylating reagent, 1-cyano-4-dimethylaminopyridinium tetrafluroborate (CDAP), to activate polysaccharides, in water, and subsequently react them with hexanediamine, in preparation for coupling proteins to the polysaccharide. CDAP activation of polysaccharide is rapid (<2 min) and efficient. CDAP can be used to activate polysaccharides of diverse chemical natures, including dextrans and pneumococcal types 6, 14, 19 and 23. The critical parameters in CDAP activation of polysaccharides were the reagent concentrations and the pH. Activation can be performed over a broad alkaline pH range, with an optimum of pH 9–10. Furthermore, proteins can be coupled to CDAP-activated polysaccharides without the use of a spacer. Direct conjugation of protein to CDAP-activated polysaccharides can be performed under mildly alkaline conditions (pH 7–9). These conditions allow CDAP to be used with alkaline-sensitive polysaccharides and proteins. Mice immunized with BSA-pneumococcal type 14 polysaccharides (Pn14) conjugates, prepared either by direct conjugation or via a spacer, had high anti-Pn14 and anti-BSA serum antibody IgG1 titers, whereas no IgG1 antibody was induced to the unconjugated components. The ease of use and mild activating conditions should prove of value in using CDAP to prepare conjugate vaccines, as well as other immunologically useful reagents. [1]

---

Specific in vitro activity data for CDAP as a pharmacological agent are not documented in the literature, as it is primarily used as a chemical reagent. The compound is not characterized for direct biological activities such as enzyme inhibition, receptor modulation, or antimicrobial effects. Its utility lies in its chemical reactivity as an activating agent for carboxylic acids in peptide synthesis.

CDAP is not used for in vivo pharmacological activity assessment as a drug compound. Its primary application is as a chemical reagent in peptide synthesis and bioconjugation. The compound is not intended to be administered to animals for pharmacological or toxicological studies. Its use is limited to in vitro chemical synthesis applications.

Activation of polysaccharides [1]
Polysaccharide was activated with CDAP according to the following general procedure with variations described in the figure legends. CDAP was made up at 100 mg ml-1 in acetonitrile and stored at - 20°C for up to 1 month. CDAP was slowly pipeted into a vortexed solution of polysaccharide in water (rapid addition of the organic co-solvent precipitates the polysaccharide) and 30 s later, a volume of aqueous 0.2 M triethylamine (TEA) equal to the volume of CDAP used was added. At 2.5 min, a large molar excess of a 0.5 M hexanediamine solution in either O.lM sodium borate at pH 9.3 or 0.75 M HEPES at pH 7.5, was added. The reaction mixture was allowed to stand overnight at 4”C, desalted on either a P-6 DG or a P-6 cartridge, equilibrated with saline and then further dialyzed into saline. The extent of derivatization with hexanediamine was determined using a TNBS assay for primary amines; absorbance was measured at 366 nm, using an extinction coefficient of 11000 M-1 . Polysaccharide concentrations were determined as described by Monsigny et aZ.19, using the corresponding polysaccharide as the standard. Results are expressed as moles of amine detected per 100 kDa of polysaccharide.

---

Conjugation of proteins [1]
BSA was coupled to pneumococcal type 14 derivatized with hexanediamine (prepared as described in Table 3) via a thiol-ether linkage as described. The basic protocol for conjugating protein directly to CDAP-activated polysaccharide was as follows: the polysaccharide was activated with CDAP as described above for derivatization with amines. Protein was rapidly added to a gently vortexed solution at 2 min 30 s after the CDAP was introduced. Reactions were quenched with ethanolamine for at least 1 h before gel filtration on a S300HR or S400HR column, equilibrated with saline. Further details and variations on the basic protocol are described in the figure legends. The peak tube from the void volume was assayed for protein by the Bradford method using BioRad protein reagent, with BSA as the standard. Polysaccharide concentrations were determined by the method of Monsigny et a1.19, using the corresponding polysaccharide as the standard. Results for protein conjugations are expressed as mg of protein per mg of polysaccharide. Conjugates used for immunizations were sterilized by passage through a Millex GV filter 0.45 pm.

---

CDAP is not used in enzyme/receptor binding assays as a test compound. Its primary applications are as an activating agent for amide bond formation in peptide synthesis. When used in research, it serves as a reagent for the activation of carboxylic acids. Standard synthetic chemistry protocols are employed for its use, including peptide coupling reactions, rather than biochemical assay procedures.

CDAP is not used in cell-based assays as a test compound. Its primary application is as a chemical reagent for peptide synthesis and bioconjugation. The compound is not characterized for direct cellular effects, cytotoxicity, or any pharmacological activity. Its use is limited to chemical synthesis applications in vitro.

CDAP is not used in animal studies as a pharmacological agent. Its primary application is as a chemical reagent in peptide synthesis and bioconjugation. The compound is not intended to be administered to animals for efficacy or safety evaluations. Its use is limited to in vitro chemical synthesis applications.

CDAP (1-Cyano-4-dimethylaminopyridinium tetrafluoroborate) has a molecular weight of 235.00 g/mol and a molecular formula of C₈H₁₁BF₄N₃. It is a white to off-white crystalline solid. The compound is used as an activating agent for amide bond formation in peptide synthesis and bioconjugation. It is typically stored under standard laboratory conditions at -20°C, protected from moisture, as it is hygroscopic.

CDAP is intended for research use only and is not approved for human therapeutic applications. As a chemical reagent, comprehensive toxicological data are not extensively documented in the publicly accessible literature. The compound may be irritating to the skin, eyes, and respiratory tract. Standard safety precautions should be observed when handling this compound, including the use of appropriate personal protective equipment. The compound should be handled in well-ventilated areas with proper waste disposal procedures.

[1]. Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents. Vaccine. 1996 Feb;14(3):190-8. doi: 10.1016/0264-410x(95)00195-7.

The general conditions described in this paper for activating polysaccharides, derivatizing polysaccharides with functional groups, or directly conjugating proteins have been proven applicable to a wide range of polysaccharides and proteins (unpublished observations). The ease of use of CD.4P allows for small-scale reactions, making it easy to determine a range of suitable reaction conditions for specific polysaccharide and protein combinations. For example, we found that the reaction mixture gelled under conditions where cyanate intermediates promoted inter- and intra-chain crosslinking and multi-point protein linkages, such as excess CDAP, elevated pH, high polysaccharide concentrations, and/or insufficient protein. This technique offers advantages such as good reproducibility, rapid reaction speed, and the ability to prepare conjugates with varying protein-polysaccharide ratios. This provides a reproducible method for studying the effect of protein-polysaccharide ratios on the antibody reactivity of conjugates. Furthermore, since similar protein-polysaccharide ratios can be obtained under a variety of experimental conditions, the effect of different degrees of protein-polysaccharide crosslinking on the immunogenicity of conjugates can be investigated. In addition to its value in preparing protein-polysaccharide constructs, CDAP-activated soluble polysaccharides can also be used to synthesize other immunological and diagnostic reagents. Many nucleophilic groups can be directly coupled to CDAP-activated polysaccharides. For example, we prepared biotinylated polysaccharides using aminobiotin for ELISA reagents; prepared trinitrophenylated polysaccharides for studying the properties of T cell-independent antigens; and prepared peptide-polysaccharide conjugates for immunogens. [1]

---

CDAP (1-Cyano-4-dimethylaminopyridinium tetrafluoroborate) (CAS#: 59016-56-7) is a chemical reagent used as an activating agent for amide bond formation in peptide synthesis and bioconjugation. This compound is not a drug and has not undergone clinical trials.

C8H10BF4N3

234.99

235.09

59016-56-7

9881151

White to off-white solid powder

196-200ºC

1.669

0

7

1

16

179

0

CN(C1=CC=[N+](C#N)C=C1)C.F[B-](F)(F)F

MBLVMDCQDCVKNE-UHFFFAOYSA-N

InChI=1S/C8H10N3.BF4/c1-10(2)8-3-5-11(7-9)6-4-8;2-1(3,4)5/h3-6H,1-2H3;/q+1;-1

4-(dimethylamino)pyridin-1-ium-1-carbonitrile;tetrafluoroborate

1-cyano-4-dimethylaminopyridinium tetrafluroborate; CDAP

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Note: Please store this product in a sealed and protected environment, avoid exposure to moisture.

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

---

Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).

View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)

---

Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).

View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

---

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

---

 (Please use freshly prepared in vivo formulations for optimal results.)